Chemical industry – Page 104
-
OpinionThe financial funfair
The financial markets can be a rollercoaster ride, writes Derek Lowe, so should chemists working in industry worry about the company share price?
-
Business
Business roundup: July 2011
World digs deep for cheaper vaccination Source: © Ben Fisher/GAVI/2011 UK Prime M inister David Cameron talked of a ’vital issue’ World leaders have pledged $4.3 billion (£2.6 billion) over the next five years to vaccinate 250 million people in developing countries with the help of the ...
-
OpinionCategorising chemists
To the unfamiliar, chemists might all look the same. But some common categories are easy to identify, explains Derek Lowe
-
Business
Business roundup: June 2011
Succinic acid plans Dutch life and material sciences company DSM and French starch company Roquette Frères are together planning to build what they say will be the largest European plant for the production of succinic acid from biological sources. To be built on the Roquette site at Cassano Spinola ...
-
OpinionWho counts as a chemist?
The map of scientific disciplines is growing ever more complex. Derek Lowe surveys the country
-
Business
Business roundup: May 2011
Pharmaceutical US approval for AZ thyroid cancer drug The US Food and Drug Administration (FDA) has approved orphan drug vandetanib for the treatment of thyroid cancer. The drug candidate is owned by pharma major AstraZeneca. The approval refers to medullary thyroid cancer that cannot be removed by surgery or ...
-
OpinionThe return of the return of natural products
'Natural products are back!' is a headline Derek Lowe has seen several times before
-
Business
Business roundup: April 2011
Pharmaceutical Forest pays $1.2bn for Clinical Data US pharma company Forest Laboratories has agreed to buy Clinical Data for $30 (£19) per share in cash, equivalent to $1.2 billion, plus $6 per share payable if Viibryd (vilazodone) reaches commercial milestones. Forest intends to use existing cash to finance the deal. ...
-
OpinionThe risk vs reward of drug discovery
Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
-
Business
Business roundup: March 2011
Venom kits for drug discovery research Drug discovery companies can now buy venom kits to help them find new avenues of investigation by high throughput screening. Each kit from Swiss company Bachem is a plate with a series of wells - each well contains peptide fragments from the venoms ...
-
OpinionElevating enzymes
Enzymes have been giving chemists inferiority complexes since day one, says Derek Lowe. But there's no denying their potential
-
Business
Business roundup: February 2011
DuPont signs $6.3 billion Danisco deal Source: © Danisco Danisco divested its flavour and sugar businesses in the last five years US chemical major DuPont has agreed to buy Danish food ingredients and enzymes company Danisco for $5.8 billion (£3.7 billion), plus $500 million of Danisco ...
-
OpinionFluorine fanatics
Some medicinal chemists can't get enough fluorines in their molecules. Derek Lowe explains the love-hate relationship
-
Business
Business roundup: January 2011
New pharma bosses take up challenge Can Ian Read (L) and Ken Frazier (R) solve the big pharma problem? Two of the big US pharma companies have appointed new chief executives. Jeff Kindler has unexpectedly retired from Pfizer after four and a half years as chief ...
-
OpinionWe need more surprises
Who's that asleep at the back? Don't be too quick to blame yourself when tedious talks and soporific seminars fail to inspire, says Derek Lowe
-
Business
Business roundup: December 2010
Polished performance from Pradaxa The US Food and Drug Administration (FDA) has approved Pradaxa (dabigatran), made by Boehringer Ingelheim, for the prevention of stroke and blood clots in patients with abnormal heart rhythm, known as atrial fibrillation. Source: © Paul Gunning / Science Photo Library ...
-
NewsCompany snapshot: Novo Nordisk
What's the secret of Danish diabetes specialist Novo Nordisk's success?
-
OpinionThe 'blockbuster mentality’
Should companies focus on big markets and the blockbuster dream? The more modern approaches are not without risks, says Derek Lowe
-
Business
Business roundup: November 2010
Sanofi gets hostile Sanofi-Aventis has taken its $69-per-share (£44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board - which has unanimously rejected the offer and advised shareholders to hold fast. The Sanofi offer, which values Genzyme ...
-
OpinionThe quiet comeback of 'combi-chem'
Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery